Elite Network: i-Target: Immunotargeting of cancer

i-Target: Immunotargeting of cancer

Malignant diseases represent an unmet medical challenge with a huge social and economical impact. Early diagnosis and optimized operative, medical and radiotherapeutic treatments often cure early stage cancers. The prognosis for many patients with advanced-stage diseases, however, remains dismal. An important achievement of the last decade is the use of the body's own immune system to treat patients.

The International Doctorate Program at a glance

DegreePhD
Duration of studyEight semesters
Place of studyMunich, Erlangen
Admission requirementsExcellent master’s degree in natural science or students of medicine with outstanding first part of medical exam
LanguageEnglish
Application deadlineAccording to advertisement
HeadProf. Dr. med. Stefan Endres
CoordinatorPD Dr. med. Sebastian Kobold
Contact the coordinator
Further informationWebsite i-Target: Immunotargeting of cancer

Investigate innovative immune therapies

Tumor immunotherapy is currently subject of intense scientific and clinical development. The requirements of well trained scientists in this research field is rapidly increasing, both in industry and academy.

There are currently no structured training programs in Germany to train prospective scientists specifically in the field of immuno­therapies. To fill this gap, a team of ten Bavarian professors under the lead of the LMU Munich (speaker: Prof. Endres) have joined forces to investigate inno­vative immune therapies and to train talented PhD-students in this highly competitive research field.

Portrait photo: Prof. Dr. Stefan Endres

The funding provided by the Elite Network of Bavaria allows the networking of leading research groups in Bavaria to immunotherapy of tumors – one of the most scientifically and clinically up-to-date research areas in biomedicine.

Prof. Dr. Stefan Endres

The training program includes weekly seminars, quarterly workshops and annual conferences. A special character of the program is the intense cooperation with the industry and international secondments as an integral part of the PhD-projects.

Three fields of immunotherapy will be investigated: Targeted cell-based therapies, targeted antibody therapy and immunomodulatory therapy (that counteracts tumor-derived immunosuppression).

Snippets of the program

Harvard Retreat 2019

i-Target’s long-standing partnership with the Harvard Im-munology Program continues to grow.

Read the report

Two young man standing in front of the Harvard Medical School entrance.

CARMOUFLAGE

i-Target research team receives the m4 Award for its T cell therapy platform CARMOUFLAGE.

Read the report

Three scientists have a certificate in their hands and smile into the camera. On the left is the ministerial director and on the right the managing director of BioM.

Snippets of the research

Anti-PD-1 antibodies

Philipp Metzger, one of the doctoral students in the i-Target program, investigates the function of suppressive myeloid cells in pancreatic cancer and their reprogramming.

T cells and interleukin 21

Romy Loschinski investigates the impact of interleukin 21 on T cell metabolism, fitness and differentiation in her thesis.

New T cell therapy technology

Ms Karches examined in her doctoral thesis bispecific antibodies that enables synthetic agonistic receptor-transduced T cells for tumor immunotherapy